Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 529 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR Garbage Men Finally Meet Cancer-Free Toddler After Bonding From Afar August 7, 2019 Researchers Discover Genetic Marker That Increases Risk Of Premenopausal Breast Cancer August 2, 2019 ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current... May 19, 2021 Cancer Survivor And His Organ Donor Run NYC Marathon Together To... November 7, 2021 Load more HOT NEWS Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... New on NCI’s Websites for November 2021 ΟΓΚΟΙ ΕΓΚΕΦΑΛΟΥ MGUS to Myeloma: Study Suggests Risk of Progression Can Change
